ALK and non-small cell lung carcinoma: The safety profile reported in this PMS study is also in line with the safety profile observed in the Japanese subgroup of patients (N = 24) from the ASCEND-2 study (single-arm, open-label, multicentre, phase II study of ceritinib in adult patients with ALK+ NSCLC previously treated with chemotherapy and crizotinib)6.